Ask AI

Capsule Summary Slidesets

Share

Program Content

Activities

  • AZD0486 for RR FL
    AZD0486, a CD19 x CD3 Bispecific Antibody, for Relapsed/Refractory Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2024

  • MITHIC FL1 Mosunetuzumab
    MITHIC-FL1: Phase II Study of Single-Agent Mosunetuzumab in Patients With Newly Diagnosed Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2024

  • BRUIN CLL-321
    BRUIN CLL-321: Phase III Trial of Pirtobrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab in Covalent BTK Inhibitor–Pretreated CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2024

  • ALTAMIRA
    ALTAMIRA: Phase II Trial of Acalabrutinib + Rituximab as First-line Treatment for Mantle Cell Lymphoma in Patients Aged ≥60 Yr
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

  • inMIND
    inMIND: A Phase III Study of Tafasitamab, an Anti-CD19 Antibody, Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

  • ECOG ACRIN EA4151
    ECOG-ACRIN EA4151: Phase III Trial of Autologous Hematopoietic Cell Transplantation in MRD-Negative Patients With Mantle Cell Lymphoma in First Complete Remission
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

  • AMPLIFY
    AMPLIFY: First-line Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs CIT in CLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation